Greenwich LifeSciences (GLSI) to Release Quarterly Earnings on Wednesday

Key Points

• Greenwich LifeSciences (GLSI) is expected to report its quarterly earnings on August 13th, with analysts forecasting a loss of ($0.24) per share.
• In its last earnings report, Greenwich missed expectations by reporting ($0.25) EPS, and analysts predict a total of ($1 EPS) for both the current and next fiscal years.
• Institutional investors have been active, with notable increases in holdings, including a 48.7% increase by Rhumbline Advisers in the first quarter.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 20th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). On average, analysts expect Greenwich LifeSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Greenwich LifeSciences Stock Up 4.4%

NASDAQ:GLSI traded up $0.51 during midday trading on Friday, hitting $12.18. The company had a trading volume of 92,285 shares, compared to its average volume of 78,986. The company has a market capitalization of $162.82 million, a PE ratio of -9.67 and a beta of 1.65. Greenwich LifeSciences has a 52-week low of $8.06 and a 52-week high of $16.50. The stock's fifty day moving average price is $10.29 and its 200-day moving average price is $10.64.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Greenwich LifeSciences by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock worth $1,261,000 after buying an additional 1,972 shares during the period. Strs Ohio bought a new stake in Greenwich LifeSciences during the first quarter worth about $177,000. Rhumbline Advisers grew its holdings in Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after purchasing an additional 3,168 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their target price on Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a research report on Monday, April 21st.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.